Download PDF

1. Company Snapshot

1.a. Company Description

Regeneron Pharmaceuticals, Inc.discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.


The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Show Full description

1.b. Last Insights on REGN

Breaking News: Regeneron Pharmaceuticals, Inc. reported Q1 2026 earnings, beating estimates with $9.47 per share, up from $8.22 per share a year ago. Revenue rose 19% year-over-year to $3.605 billion, surpassing forecasts of $3.49 billion. The company also announced a new share repurchase program worth up to $3 billion. Multiple analysts have weighed in, with some recommending a hold. Regeneron Pharmaceuticals, Inc. provided a business update alongside its financial results. The company's adjusted earnings and revenue exceeded Wall Street forecasts.

1.c. Company Highlights

2. Regeneron Surges with 19% Revenue Growth and Robust Pipeline Momentum

Regeneron Pharmaceuticals delivered a stellar first‑quarter 2026 performance, with total revenues climbing 19% to $4.9 billion and non‑GAAP earnings per share up 15% to $9.47—surpassing consensus estimates of $8.91. The company’s gross margin guidance now sits between 77% and 78%, reflecting efficient cost management amid strong product sales. A single staff citation underscores the cash generation: “Regeneron’s CFO highlighted that the $848 million free cash flow fuels the new $3 billion share repurchase program.” Market‑price multiples are currently priced at a P/E of 16.62, a P/S of 4.92, and an EV/EBITDA of 12.74, indicating moderate valuation relative to peers, while a dividend yield of 0.51% and free cash flow yield of 5.66% signal modest but growing shareholder value creation.

Publication Date: May -01

📋 Highlights
  • Revenue & Earnings Growth: Total revenues surged 19% to $4.9 billion, with non-GAAP EPS rising 15% to $9.47.
  • DUPIXENT Sales Surge: Global net sales increased 31% to $4.9 billion, driven by strong demand across indications.
  • EYLEA HD & Libtayo Growth: EYLEA HD U.S. sales jumped 52% to $468 million; Libtayo sales grew 54% to $438 million.
  • Share Repurchase Program: $3 billion share repurchase announced, alongside $800 million in Q1 buybacks, with $15.8 billion in cash reserves.
  • Pipeline Advancements: FDA approval of Otarmeni for genetic hearing loss and positive Phase III data for cemdisiran in myasthenia gravis.

Revenue Growth & Profitability

The 19% revenue lift is anchored by a 31% constant‑currency rise in DUPIXENT net sales ($4.9 billion) and a 52% jump in EYLEA HD U.S. net product sales ($468 million). Global Libtayo sales grew 54% to $438 million, driven by expanded skin indications. These gains, combined with a solid gross margin outlook, reinforce Regeneron’s top‑line resilience and operational efficiency.

Top Brands Performance

EYLEA HD and DUPIXENT continue to dominate the market, with EYLEA HD’s U.S. sales reaching $468 million and DUPIXENT’s global sales hitting $4.9 billion. The company projects sequential demand growth for EYLEA HD in Q2, while anticipating a modest decline in overall EYLEA demand. These dynamics suggest a strong near‑term commercial runway for the flagship ophthalmology and dermatology assets.

Pipeline Highlights

Regeneron’s pipeline gains momentum with FDA approval of Otarmeni for genetic hearing loss and positive Phase III data for cemdisiran in generalized myasthenia gravis. Ongoing studies in complement‑mediated diseases, oncology (fianlimab, Lynozyfic, odronextamab), and obesity (olatorepatide) position the company for future blockbuster opportunities. The strategic focus on siRNA and C5 approaches underscores a diversified therapeutic strategy.

Capital Allocation & Shareholder Returns

Cash flow strength enabled a $800 million share repurchase in Q1, while the newly announced $3 billion program signals continued commitment to returning capital. Regeneron also secured a Most Favored Nation pricing agreement with the U.S. government, enhancing Medicare accessibility and reinforcing its value proposition.

Strategic Partnerships & Market Outlook

The company remains open to life‑cycle expansion with Sanofi, and CEO Leonard Schleifer expressed willingness to explore collaboration opportunities. With a 10.7% revenue growth projection for the next year, Regeneron’s robust financials, pipeline depth, and shareholder‑friendly initiatives collectively paint a favorable outlook for investors and patients alike.

3. NewsRoom

Card image cap

Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?

May -02

Source: fool.com

Card image cap

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Apr -30

Source: benzinga.com

Card image cap

Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Apr -29

Source: defenseworld.net

Card image cap

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript

Apr -29

Source: seekingalpha.com

Card image cap

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Apr -29

Source: benzinga.com

Card image cap

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength

Apr -29

Source: zacks.com

Card image cap

Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

Apr -29

Source: zacks.com

Card image cap

Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength

Apr -29

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.30%)

6. Segments

Discovery, Development, and Commercialization of Medicines for Serious Diseases

Expected Growth: 12.3%

Regeneron's innovative pipeline and commercialization of medicines for serious diseases drive growth, with increasing focus on ophthalmology, oncology, and immunology.

7. Detailed Products

EYLEA

A vascular endothelial growth factor (VEGF) inhibitor used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Dupixent

A monoclonal antibody that inhibits the action of interleukin-4 and interleukin-13, used to treat moderate-to-severe atopic dermatitis and asthma.

Praluent

A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor used to treat high cholesterol.

Libtayo

A programmed death receptor-1 (PD-1) inhibitor used to treat cutaneous squamous cell carcinoma.

Inmazeb

A monoclonal antibody used to treat Zaire ebolavirus infection.

Evkeeza

A monoclonal antibody used to treat homozygous familial hypercholesterolemia.

8. Regeneron Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Regeneron Pharmaceuticals, Inc. has a low threat of substitutes due to its unique biotechnology products and strong research and development capabilities.

Bargaining Power Of Customers

Regeneron Pharmaceuticals, Inc. has a medium bargaining power of customers due to the presence of a large number of customers, but the company's strong brand reputation and product offerings mitigate this power.

Bargaining Power Of Suppliers

Regeneron Pharmaceuticals, Inc. has a low bargaining power of suppliers due to its strong relationships with suppliers and its ability to negotiate favorable terms.

Threat Of New Entrants

Regeneron Pharmaceuticals, Inc. has a high threat of new entrants due to the growing demand for biotechnology products and the increasing number of new entrants in the market.

Intensity Of Rivalry

Regeneron Pharmaceuticals, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 9.43%
Debt Cost 3.95%
Equity Weight 90.57%
Equity Cost 4.78%
WACC 4.70%
Leverage 10.41%

11. Quality Control: Regeneron Pharmaceuticals, Inc. passed 9 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
AbbVie

A-Score: 6.7/10

Value: 3.1

Growth: 4.7

Quality: 7.2

Yield: 7.0

Momentum: 9.5

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
McKesson

A-Score: 6.1/10

Value: 5.4

Growth: 8.3

Quality: 4.5

Yield: 0.0

Momentum: 9.5

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Innoviva

A-Score: 5.5/10

Value: 4.7

Growth: 5.4

Quality: 6.6

Yield: 0.0

Momentum: 8.0

Volatility: 8.0

1-Year Total Return ->

View Full Report
Stock-Card
Regeneron Pharmaceuticals

A-Score: 4.9/10

Value: 4.0

Growth: 6.4

Quality: 8.8

Yield: 0.0

Momentum: 4.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Vertex Pharmaceuticals

A-Score: 4.0/10

Value: 1.5

Growth: 3.8

Quality: 8.9

Yield: 0.0

Momentum: 3.5

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Moderna

A-Score: 3.0/10

Value: 7.7

Growth: 2.3

Quality: 4.8

Yield: 0.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

701.42$

Current Price

701.42$

Potential

-0.00%

Expected Cash-Flows